{"schema_version":"secwatch.filing_event.v1","accession":"0001689375-26-000003","form_type":"8-K","ticker":"TRDA","cik":"0001689375","company_name":"Entrada Therapeutics, Inc.","filed_at":"2026-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.895508+00:00","generated_at":"2026-05-16T11:13:23.868568+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Entrada reports ~$296M cash, completes DMD cohort 1, expands pipeline into ocular disease with ENTR-801","bullets":["Preliminary cash, cash equivalents and marketable securities of ~$296M as of Dec 31, 2025; cash runway into Q3 2027.","Completed dosing of Cohort 1 in global Phase 1/2 MAD study of ENTR-601-44 (exon 44 skipping) for DMD.","On track to report ELEVATE-44-201 data from first cohort in Q2 2026; ELEVATE-45-201 data in mid-2026.","Received UK MHRA authorization for Phase 1/2 ENTR-601-50; expect global initiation by end 2026 and regulatory apps for ENTR-601-51 in 2026.","Expanded into ocular diseases: selected ENTR-801 (Usher syndrome type 2A) as first candidate; expects second candidate in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001689375-26-000003","json":"https://secwatch.observer/filing/0001689375-26-000003.json","markdown":"https://secwatch.observer/filing/0001689375-26-000003.md","text":"https://secwatch.observer/filing/0001689375-26-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689375/000168937526000003/0001689375-26-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689375/000168937526000003/trda-20260108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:13:23.868568+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}